Mainz, September 23, 2017 - The 1st Crick International Cancer Conference will bring together leading cancer scientists from all over the world to discuss the latest findings in cancer metabolism, the tumor microenvironment, and how the cancer genotype changes over time. In addition to lectures from world leading researches in the field, there will be many opportunities for early stage researchers to present their work in the form of short talks and posters.
In this context, on September 24 Prof. Ugur Sahin will give a presentation at 11:30-12:00 in Session 3: Tumor immune system interactions. The title of the lecture is: Individualized Cancer Immunotherapy.
Further information on the event can be found on the official website.
The 1st Crick International Cancer Conference will bring together leading cancer scientists from all over the world to discuss the latest findings in cancer metabolism, the tumor microenvironment, and how the cancer genotype changes over time.
Mainz, September 23, 2017 - The Annual Meeting of the Leopoldina National Academy of Sciences will be held on 22 and 23 September in Halle (Saale). The congress, entitled "Changes of the Genome - Challenges for the Future", will address new developments in molecular biology methods of genome editing . The topics of the event in Halle (Saale) are the foundations of programmable "Gene-Scissors", genome editing in clinical research, perspectives of the application as well as societal and legal perspectives of the new methods.
In this context, Prof. Ugur Sahin will give a presentation in Session III: Perspectives of the Application (Saturday, 23. September at 9:15-10:00.) The title of the lecture is: Targeting the mutanome for immunotherapy against cancer: Genomically tailored drugs.
Mainz, September 23, 2017 - The Annual Meeting of the Leopoldina National Academy of Sciences will be held on 22 and 23 September in Halle (Saale).
Mainz, September 21, 2017 - The working group Dermatological Oncology (ADO) organizes from 21-23 September the 27th German Skin Cancer Congress in the Rheingoldhalle Mainz. On September 21st at 4:15 pm, Ugur Sahin will give a presentation on vaccination in Session IV: Antigen-Specific Immunotherapy (Gutenberg B).
Further information on the event can be found on the official website.
Mainz, September 21, 2017 - The working group Dermatological Oncology (ADO) organizes from 21-23 September the 27th German Skin Cancer Congress in the Rheingoldhalle Mainz.
Among nucleic acid-based delivery platforms, self-amplifying RNA (saRNA) vectors are of increasing interest for applications such as transient expression of recombinant proteins and vaccination. Although saRNA is a promising technology, antigen expression from saRNA is limited by the host cells’ innate interferon response. TRON’s Tim Beissert and colleagues show, in an upcoming issue of Human Gene Therapy, that by delivering additional mRNA encoding viral interferon inhibitors with the saRNA to human fibroblasts, vaccine expression could be rescued. These findings could be exploited to increase bioavailability of encoded antigens, reduce the effective dose and thus manufacturing costs in all saRNA applicational fields.
Citation: Beissert, T., Koste, L., Perkovic, M., Walzer, K.C., Erbar, S., Selmi, A. Diken, M., Kreiter, S., Türeci, Ö., Sahin, U. Improvement of in vivo expression of genes delivered by self-amplifying RNA using Vaccinia Virus immune evasion proteins. Hum Gene Ther. 2017. doi: 10.1089/hum.2017.121
Mainz, September 2017 – On September 14, Prof. Federico Garrido from the University of Granada Medical School will be visiting Mainz in the context of our Seminars in Translational Oncology series (SITO). You are cordially invited to his talk at 5 pm c.t. in building 708 of the University Medicine Mainz.
The title of his talk is:
The Escape of Cancer from T Cell Mediated Immune Surveillance: HLA Class-I Loss and Tumor Tissue Architecture
The presentation is open to everybody.
Prof. Federico Garrido is Professor of Immunology at the University of Granada Medical School and head of the Dept. of Clinical Analysis & Immunology at the Hospital Universitario Virgen de las Nieves, Granada, Spain. After obtaining his MD and PhD degrees from the University of Granada in 1974, Prof. Garrido went on as a postdoctoral fellow at the laboratory of Dr. Hilliard Festenstein at the London Hospital Medical College in London, investigating the immunogenetics of the MHC (H-2) system by typing mouse tumour cells for H-2 expression. After returning to Granada in 1981 he continued his research on HLA typing of human tumour tissues. Prof. Garridos research focuses on the expression of HLA antigens in tumours and the role that these molecules play on tumour evasion from the immune system.
Please find more information on Prof. Garridos research and his publications at: https://www.ncbi.nlm.nih.gov/pubmed/?term=Garrido+F%5BAuthor%5D
We look forward to his visit and the interesting scientific discussions.
Mainz, September 2017 – Am 14. September kommt im Rahmen der Seminarreihe in Translational Oncology (SITO) Prof. Federico Garrido der Universität von Granada Medical School nach Mainz. Sie sind herzlich zu seinem Vortrag um 17.00 Uhr c.t. in Gebäude 708 der Universitätsmedizin Mainz eingeladen.
Mainz, September 6, 2017 - Individualized cancer immunotherapy
Prof. Ugur Sahin, Managing Director (Science and Research) and Co-Founder of TRON, will talk at the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in our hometown Mainz. His talk is titled "Individualized Cancer Immunotherapy - Exploring a new landscape" and will cover the implementation of an RNA-based approach to mobilize immunity against the full spectrum of cancer mutations. For one, we were able to demonstrate in mouse tumor models that a substantial fraction of the mutanome is immunogenic and that these neo-epitopes are preferably recognized by CD4+ T cells (Nature. 2015). In addition, a phase I study in humans with stage III and IV melanoma patients was conducted, where the patients were vaccinated with synthetic RNA encoding multiple neo-epitopes selected from their own cancer mutanome (Nature. 2017). The findings from preclinical and clinical studies will be presented together with the basic concepts behind individualized cancer immunotherapies and the exploited methods and technologies.
TRON in the Media
Welcome to TRON
TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz is a biopharmaceutical research organization that pursues new diagnostics and drugs for the treatment of cancer and other severe diseases with high medical need. A focus of TRON is the development of novel platforms for individualized therapies and biomarkers, translating basic research into drug applications. TRON partners with academic institutions, biotech companies and the pharmaceutical industry, executing research with leading-edge technologies and supporting the development of innovative drugs to promote human health.